WuXi Biologics says bispecific platform could ‘transform the industry’

By Flora Southey contact

- Last updated on GMT

(Image: Getty/liulolo)
(Image: Getty/liulolo)

Related tags: Wuxi biologics, China, Bispecific antibodies

The Chinese CDMO announced plans to launch its bispecific platform, ‘WuXiBody’, in its half-yearly report, which records “phenomenal” revenue growth.

WuXi Biologics’ 2018 interim report​ indicates strong year-on-year growth for the contract development and manufacturing organisation (CDMO). Revenue was reported to be up by 61.2% on 2017 figures, with gross profit rising to 56.9% to RMB 414.7m ($60.6m).

While gross profit margin was down to 39.3% – as compared to 40.4% for the same period last year – the firm said it would have reported a figure of approximately 41.4%, when foreign currency impact was excluded.

The firm also announced greater investment into R&D, including RMB 56.2m this year to date, representing a year-on-year increase of 54.4%, which contributed to WuXi Biologics’ latest development platform, the ‘WuXiBody’.

“As a result of our R&D investment for the last three years, we are launching a new proprietary, potentially best-in-class bispecific platform, called WuXiBody, which will expedite bispecific development by 6-18 months and at the same time tremendously reduce bispecific manufacturing cost, a current limitation of most bispecific platforms,” ​said the firm in a statement​.

Bispecific antibodies bind to two different epitopes either on the same or on a different, target.

“We are excited about the launch of our proprietary, bispecific technology platform, which can potentially transform the industry,” ​added CEO Chris Chen.

In addition, the CEO said WuXi Biologics plans to explore entry into “new frontiers of biotherapeutics”​, such as cancer vaccines. “These new modalities will drive the future growth of WuXi Biologics,” ​said Chen.

Expanding beyond China

The report also highlights the firm’s investments outside of China. This year to date, the CDMO instigated capacity expansions in Ireland​, Singapore​, and the US​.

“These facilities [including investments in China] will increase our manufacturing capacity to approximately 220,000L, further expand our customer base, attract more local talent and ensure a global diversified and robust supply chain network,” ​said the company.

The CDMO also flagged an international development and manufacturing agreement with US-based Immune Pharmaceuticals for the production of monoclonal antibody (mAb) Bertilimumab.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more